New

Controls & Reference Materials

Seraseq® ctDNA EGFR ex19del Mutation Mix AF0.1%

Material Number 0710-0709
Size 1 x 20 uL
Inventory Status In Stock
Unit EA

Driver mutations in the EGFR, BRAF, and KRAS genes represent a combined ~60% of all genomic variants driving oncogenesis of many solid tumor diseases, especially lung cancer. SeraCare is expanding its liquid biopsy portfolio with the addition of low-plex (single-gene) reference materials for clinically-validated biomarkers in these genes as ground-truth standards for molecular testing of circulating tumor DNA patient samples by PCR or NGS technologies. These products are designed for validation and standardization of clinical biomarkers in CLIA/CAP-accredited laboratory-developed tests (LDTs).

The Seraseq ctDNA EGFR ex19del Mutation Mix product has an allele frequency of 0.1%.

  • Size distribution similar to native cfDNA
  • Offered as a purified DNA mixture for ease of use during processing
  • Mutation precisely quantitated with digital PCR
  • Single well-characterized GM24385 human genomic DNA as background wild-type material
  • Manufactured in GMP-compliant and ISO 13485-certified facilities

Seraseq ctDNA EGFR ex19del Mutation Mix AF0.1%

Doc type
Product Report
Lot #
10383328

Seraseq ctDNA EGFR ex19del Mutation Mix AF1% & AF0.1%

Doc type
Package Insert
Product Specifications
# of variants 1
Allele Frequency 0.1%
Fragment Size ~170bp
Concentration 10 ng/µL
Fill Size 20 µL
Total DNA 200 ng
Buffer Tris/EDTA (TE)